LifeStance Health Group (LFST)
(Delayed Data from NSDQ)
$6.74 USD
0.00 (0.00%)
Updated Sep 11, 2024 04:00 PM ET
After-Market: $6.74 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
D Value A Growth F Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$6.74 USD
0.00 (0.00%)
Updated Sep 11, 2024 04:00 PM ET
After-Market: $6.74 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
D Value A Growth F Momentum C VGM
Zacks News
LifeStance Health Group (LFST) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
LifeStance Health (LFST) delivered earnings and revenue surprises of 0% and 6.31%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
LifeStance Health Group (LFST) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
LifeStance Health (LFST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Chemed (CHE) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Chemed (CHE) delivered earnings and revenue surprises of 1.70% and 0.63%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Amedisys (AMED) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Amedisys (AMED) delivered earnings and revenue surprises of 12.62% and 0.36%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks Industry Outlook Highlights Option Care Health, LifeStance Health, Addus HomeCare and Pennant
by Zacks Equity Research
Option Care Health, LifeStance Health, Addus HomeCare and Pennant have been highlighted in this Industry Outlook article.
4 Stocks to Watch Amid a Challenging Outpatient Home Health Industry
by Zacks Equity Research
Despite the macroeconomic challenges, rising dependence on telehealth and the dominance of AI are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry. OPCH, LFST, ADUS and PNTG are well poised to gain from the prospects.
LifeStance Health Group (LFST) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
LifeStance Health (LFST) delivered earnings and revenue surprises of 26.67% and 0.97%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Oak Street Health, Inc. (OSH) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Oak Street Health, Inc. (OSH) delivered earnings and revenue surprises of 11.11% and 1%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
U.S. Physical Therapy (USPH) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
U.S. Physical Therapy (USPH) delivered earnings and revenue surprises of 5.45% and 2.34%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
LifeStance Health Group (LFST) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
LifeStance Health (LFST) delivered earnings and revenue surprises of -58.33% and 1.09%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
U.S. Physical Therapy (USPH) Lags Q2 Earnings and Revenue Estimates
by Zacks Equity Research
U.S. Physical Therapy (USPH) delivered earnings and revenue surprises of -3.23% and 1.84%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
LifeStance Health (LFST) Soars 6.2%: Is Further Upside Left in the Stock?
by Zacks Equity Research
LifeStance Health (LFST) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.